Holdings of Fairmount Funds Management LLC
11 declared positions · as of Mar 31, 2026
Original filing · Ten largest lines: 98.9 % of the equity sleeve
Sector breakdown
- Unattributed 100.0 %
Titelia classification, company by company. The unattributed share stays visible.
Currency breakdown
- USD 100.0 %
The quoted currency of each line, as declared.
Country breakdown
- US 100.0 %
Shares computed on the equity sleeve.
| Rank | Country | Lines | Value | Share |
|---|---|---|---|---|
| 1 | US | 11 | 1.3B $ | 100.00 % |
Positions
| Rank | Company | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | DAMORA THERAPEUTICS INC | 8,713,000 | 225.7M $ | |
| 2 | Dianthus Therapeutics Inc | 2,537,191 | 212.9M $ | |
| 3 | Cogent Biosciences Inc | 5,503,418 | 211.8M $ | |
| 4 | Spyre Therapeutics Inc | 4,018,101 | 202.7M $ | |
| 5 | Oruka Therapeutics Inc | 3,705,262 | 181.7M $ | |
| 6 | Viridian Therapeutics Inc | 3,914,458 | 76.6M $ | |
| 7 | Enliven Therapeutics Inc | 1,855,644 | 72.7M $ | |
| 8 | JADE BIOSCIENCES INC | 4,553,494 | 64M $ | |
| 9 | ZENAS BIOPHARMA INC | 2,359,025 | 46.1M $ | |
| 10 | Apogee Therapeutics Inc | 298,647 | 25.1M $ | |
| 11 | Inhibikase Therapeutics Inc | 8,625,000 | 14.5M $ |